Shanghai Haohai Biological Technology , Ltd. Profit Margin

Shanghai Haohai Biological Technology , Ltd. posts a profit margin of 4.78% as of September 2026. That compares with 15.34% in the prior-year period — down 68.8% year over year. That is below the Healthcare sector average of 9.48%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Shanghai Haohai Biological Technology , Ltd.'s profit margin was 15.34%. The latest reading is 4.78% — a 68.8% year-over-year decrease (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 9.48% is typical. Shanghai Haohai Biological Technology , Ltd.'s 4.78% is lower that level. That is roughly 49.6% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Shanghai Haohai Biological Technology , Ltd.'s profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 4.78% as of September 2026; use YoY and peer views to separate noise from signal.

Context for 688366.SS's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 9.48%), and (3) consistency with growth and profitability. This page covers the first two; Shanghai Haohai Biological Technology , Ltd.'s other metric pages and overview cover the third.